Next Generation Antibody Therapeutics: From Discovery to Patient (Q5)
February 19-22, 2023
| Fairmont Banff Springs, Banff, AB, Canada
Pamela M. Holland and James A. Wells
Scholarship Deadline: Nov. 28, 2022 | Abstract Deadline: Nov. 28, 2022 | Early Registration Deadline: Dec. 15, 2022
Sunday, February 19, 2023
| 4:00–8:00 PM |
Arrival and Registration |
Riverview Lounge |
| 6:00–8:00 PM |
Welcome Mixer |
Riverview Lounge |
Monday, February 20, 2023
| 7:00–8:00 AM |
Breakfast |
Alberta/New Brunswick |
| 8:00–9:00 AM |
Welcome and Keynote Address (Joint) |
Cascade Ballroom |
| |
* Pamela M. Holland, InduPro
Session Chair |
|
| |
* Pablo Umaña, Roche Innovation Center Zürich
Session Chair |
|
| |
* James A. Wells, University of California, San Francisco
Session Chair |
|
| |
Tomoyuki Igawa, Chugai Pharmaceutical
Conditional Activation of Antibody Therapeutics in the Tumor Microenvironment |
|
| 9:00–11:15 AM |
Conditional Targeting with Multi-Specific Engagers (Joint) |
Cascade Ballroom |
| |
Pamela M. Holland, InduPro
Session Chair |
|
| |
Pablo Umaña, Roche Innovation Center Zürich
Session Chair |
|
| |
Katarina Pance, Epi Biologics
Bispecific Antibodies for Targeted Degradation of Extracellular Proteins |
|
| |
Wendy Ritacco, AbbVie Bioresearch Center
A Targeted Conditional PSCA-CTLA4 DVD-Ig for Immuno-Oncology: POC in Syngeneic Tumor and Metastasis Models |
|
| |
Edward van der Horst, Sensei Biotherapeutics
Short Talk: Short Talk: SNS-101, A Conditionally Active Anti-VISTA Antibody, Potentiates Anti-tumor Effects of PD-1 Blockade and Displays Favorable Pharmacokinetic and Cytokine Release Characteristics |
|
| 9:30–9:50 AM |
Coffee Break |
Riverview Lounge |
| 11:15–1:00 PM |
Poster Setup |
Alberta/New Brunswick |
| 11:15–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
Alberta/New Brunswick |
| 2:30–4:30 PM |
Workshop 1: New Ab Therapeutics and Engineering Platforms |
Cascade Ballroom |
| |
Yanay Ofran, Biolojic
A Computationally Designed Selective Agonist/Antagonist anti-IL-2 Antibody Redirects Endogenous Human IL-2 to Enhance Teff Function, while Antagonizing Tregs |
|
| |
Maxwell A Stefan, Twist Biosciences
Discovery of Novel Complement component 5a Receptor 1 Antagonistic Antibodies Using a Target-Specific Generated Phage Library |
|
| |
Nazanin Rohani Larijani, National Research Council
CAIX VHH-based Therapies for Specific Targeting of Hypoxic Solid Tumor Areas |
|
| |
Frank J. Beurskens, Genmab
Engineered Mutually-dependent IgG Antibody Combinations that Selectively Act on Cells Co-expressing Two Antigens |
|
| |
Adam Zwolak, Janssen R&D
Mucosal Targeting of Antibodies: Hitchhiking on the Polymeric Ig Receptor |
|
| |
* Christoph Rader, UF Scripps Biomedical Research, University of Florida
Concerted Antibody and Antigen Discovery by Differential Whole-cell Phage Display Selections and Multiomic Target Deconvolution |
|
| |
Malin Jönsson, KTH Royal Institute of Technology
CaRA - Calcium-Regulated Affinity Domains with Novel Target Specificities for Enhanced Therapeutic Potential |
|
| |
Lorenzo Maso, NYULMC
Creating MHC-restricted Neoantigens with Covalent Inhibitors that can be Targeted by Immune Therapy |
|
| 4:30–5:00 PM |
Coffee Available |
Riverview Lounge |
| 5:00–7:00 PM |
Antibody Modality |
Cascade Ballroom |
| |
Shelley Ackerman, Bolt Biotherapeutics
Remote Presentation: Development of Immune Stimulating Antibody Conjugates to Promote Durable Antitumor Immunity |
|
| |
* John R. Desjarlais, Xencor, Inc.
A Variety of Antibody-based Modalities for T Cell Signals 1, 2, and 3 |
|
| |
Sai T. Reddy, ETH Zurich
Engineering Synthetic T Cell Receptors for Enhanced Potency and Specificity |
|
| |
Francisco Leon, Provention Bio, Inc
Bi-Specific B Cell Targeting Diabody DART for Gene Therapy, SLE and Other Autoimmune Disorders |
|
| 7:00–8:00 PM |
Social Hour with Lite Bites |
Alberta/New Brunswick |
| 7:30–10:00 PM |
Poster Session 1 |
Alberta/New Brunswick |
Tuesday, February 21, 2023
| 7:00–8:00 AM |
Breakfast |
Alberta/New Brunswick |
| 8:00–11:00 AM |
New Approaches Toward Target Identification |
Cascade Ballroom |
| |
* Bernd Wollscheid, ETH Zürich
Leveraging Surfaceome Nanoscale Organization for Theranostics |
|
| |
James A. Wells, University of California, San Francisco
Cell Surface Protolysis for Neo-Epitopes |
|
| |
Niyi Fadeyi, InduPro
A Photocatalytic Toolbox for Cataloging Inherent Protein Proximity at the Membrane Surface |
|
| |
Erica Ollmann Saphire, La Jolla Institute for Immunology
Structural Biology of Viruses Toward Therapeutic Development |
|
| |
Garrett Rappazzo, Adimab LLC
Short Talk: Short Talk: Rapid Engineering of Soluble T Cell Receptors for Enhanced Affinity via a High-throughput Yeast-based Platform |
|
| 9:00–9:20 AM |
Coffee Break |
Riverview Lounge |
| 11:00–1:00 PM |
Poster Setup |
Alberta/New Brunswick |
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
Alberta/New Brunswick |
| 2:30–4:00 PM |
Workshop 2: Emerging Approaches to Expand Biologic Therapies |
Cascade Ballroom |
| |
* Andrea Imle, BioNTech SE
Session Chair |
|
| |
Benjamin Bell, Merck & Co., Inc.
Enzyme Engineering of Human Hyaluronidase-1 for Subcutaneous Delivery of Biologics |
|
| |
Andrea Imle, BioNTech SE
HexaBody-CD27 Enhances Proliferation, Cytokine Secretion and Cytotoxic Activity of Activated T cells without Requirement for Fc Gamma Receptor-mediated Crosslinking |
|
| |
Jonathan Back, GlycoEra
Glycoengineered Lysosomal-Targeting Constructs (G-LyTAC) engaging ASGPR: A Novel Class of Targeted Extracellular Proteins Degraders |
|
| |
Noel T. Pauli, Adimab LLC
Efficient Antibody Discovery against Membrane-obligate Drug Targets Utilizing a Yeast-based, Single B cell Cloning Platform |
|
| |
Shaheen Farhadi, Merck & Co., Inc.
Targeting Interleukin-12 and -23 Private Receptors with Agonist Antibodies |
|
| 4:30–5:00 PM |
Coffee Available |
Riverview Lounge |
| 5:00–7:00 PM |
Emerging Costimulatory Therapies in Oncology (Joint) |
Cascade Ballroom |
| |
* Pablo Umaña, Roche Innovation Center Zürich
Off-the-Shelf Enhanced T Cell Redirection via Tumor-Targeted Costimulatory Agonist and Engager Combinations |
|
| |
Janelle Christine Waite, Regeneron
Tumor-Targeted Costimulation via Bispecific CD28 Antibodies |
|
| |
* Pamela M. Holland, InduPro
Conditional Targeting of CD28 in the Tumor Micorenvironment |
|
| |
Sara Majocchi, Novimmune SA
Tumor and Immune Checkpoint-Dependent CD28 Agonism Using Bispecific Antibodies |
|
| 7:00–8:00 PM |
Social Hour with Lite Bites |
Alberta/New Brunswick |
| 7:30–10:00 PM |
Poster Session 2 |
Alberta/New Brunswick |
Wednesday, February 22, 2023
| 7:00–8:00 AM |
Breakfast |
Alberta/New Brunswick |
| 8:00–11:00 AM |
Discovery Platforms |
Cascade Ballroom |
| |
* Jamie Spangler, Johns Hopkins University
A Suspension-based Cell-cell Interaction Platform for Membrane Protein-targeted Antibody Discovery |
|
| |
Shohei Koide, New York University Langone Health
Targeting Intracellular Proteins with Biologics |
|
| |
Mart Ustav Jr., Icosagen Therapeutics
Functional Antibodies Against Multi Span Transmembrane Proteins - Revisiting the Warburg Effect in Cancer Cells |
|
| |
Nora Karnowski, Apis Assay Technologies Ltd
Short Talk: Short Talk: Targeting Highly Homologous Pathogens With Supremely Specific Clickmers |
|
| |
Bhuvaneshwari Shunmuganathan, National University of Singapore
Short Talk: Short Talk: The Application of Advanced Antibody Engineering Methodologies for Development of Prognostic and Diagnostic Assays for COVID-19 |
|
| 9:00–9:20 AM |
Coffee Break |
Riverview Lounge |
| 11:00–5:00 PM |
On Own for Lunch |
|
| 3:00–4:30 PM |
Career Roundtable |
Alhambra |
| |
Markus G G. Manz, University Hospital Zürich
Department Chair, Prof. of Hematology |
|
| |
Francisco Leon, Provention Bio, Inc
Chief Scientific Officer, Co-Founder |
|
| |
Jamie Spangler, Johns Hopkins University
Assistant Professor |
|
| 4:30–5:00 PM |
Coffee Available |
Riverview Lounge |
| 5:00–6:45 PM |
Emerging Antibody Therapeutics in Infectious Disease |
Cascade Ballroom |
| |
* James A. Wells, University of California, San Francisco
Session Chair |
|
| |
Christopher O. Barnes, Stanford University
Structural Characterization of Antibody Responses to SARS-CoV-2 |
|
| |
Ting Y Wong, WRAIR
Short Talk: Short Talk: Murine Monoclonal Antibodies against Secreted Staphylococcus Aureus Prothrombin-activating Virulence Factors Induce Macrophage Opsonophagocytosis |
|
| |
Elizabeth Parzych, The Wistar Institute
Short Talk: Short Talk: Development of DNA-encoded, Functionally- enhanced Antibody Therapeutics against SARS-CoV-2 |
|
| |
Jason Kang, West Virginia University
Short Talk: Short Talk: Monoclonal Antibodies to Lipopolysaccharide Protect against Pseudomonas Aeruginosa Infection |
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) |
Cascade Ballroom |
| 7:00–8:00 PM |
Social Hour with Lite Bites |
Alberta/New Brunswick |
| 8:00–11:00 PM |
Cash Bar |
Alberta/New Brunswick |
Thursday, February 23, 2023
